logo
From Premium to Plunge: The Unraveling of History's Most Profitable Copper Play

From Premium to Plunge: The Unraveling of History's Most Profitable Copper Play

Globe and Mail6 days ago
President Trump's surprise 50% tariff on copper semi-finished products—paired with an exemption for refined metal—sent shockwaves through global markets, obliterating the lucrative CME-LME spread and triggering Comex copper's largest intraday plunge on record. The White House's last-minute proclamation annihilated months of fat profits for traders who had front-loaded U.S. warehouses ahead of levy day. Comex front-month futures in New York collapsed over 22%, flipping from a 30% premium to a deep discount against London Metal Exchange benchmarks as LME prices dipped only modestly. 'In a single session, the spread evaporated,' noted Daniel Ghali of TD Securities, capturing the scale of the unwind. With millions of tons of copper now stranded in U.S. depots, the once-profitable trade has become a cautionary tale of policy risk. Market Overview:
Trump's tariff twist upends copper arbitrage between Comex and LME
Commodity flows reverse as massive U.S. premiums vanish
Volatility spikes underline vulnerability to abrupt policy shifts
Key Points:
50% duties hit semi-finished copper; refined metals remain untaxed
Comex futures tumbled >22%, while LME lost under 1%
Goldman Sachs sees fundamentals intact but arbitrage pressures easing
Looking Ahead:
Speculation mounts over U.S. re-exports as warehouse stocks swell
Comex-LME spreads likely to normalize once policy clarity returns
Supply-security exemptions hint at ongoing administration focus
Bull Case:
President Trump's exemption for refined copper—while hitting semi-finished products—could ultimately secure domestic supply and support U.S. manufacturing, incentivizing longer-term investment in refinement capacity as companies adapt to the new trade regime.
With the premium on Comex futures wiped out, U.S. copper prices may normalize relative to global benchmarks, helping downstream buyers access material at more competitive rates and reducing distortions in industrial procurement.
Goldman Sachs and other analysts note that copper's fundamental supply-demand balance remains intact. Short-term volatility may give way to a more stable environment once the market digests the policy change and arbitrage pressures subside.
For sophisticated traders and institutions, the recent dislocation presents new tactical opportunities: those with nimble positioning and robust risk management can profit by arbitraging price moves as spreads re-anchor between Comex and LME.
From a broader strategic standpoint, the tariff shock is a wake-up call reinforcing the importance of supply-chain flexibility and geodiversification, prompting firms to reassess storage, sourcing, and trade execution in light of policy risks.
If and when policy clarity and exemptions are fully detailed, investor confidence in U.S. copper logistics could rebound, paving the way for renewed investment as the volatility premium dissipates.
Bear Case:
The sudden imposition of a 50% tariff on semi-finished copper products and the carve-out for refined metal destroyed months of planned arbitrage trades, triggering over 22% declines in Comex prices and stranding millions of tons in U.S. warehouses—an acute market dislocation that could lead to lasting losses and reputational risk for affected stakeholders.
Abrupt policy pivots expose the entire copper and broader commodities complex to heightened volatility and policy risk, deterring long-term investment in U.S. base-metal processing, logistics, and infrastructure.
Arbitrage profits that once attracted liquidity, inventory, and efficient commodity flows have vanished; market participants may remain gun-shy about building positions due to uncertainty about future regulatory changes or unpredictable tariff timing.
The patchwork, phased approach—with delayed refined copper tariffs—unsettles trade partners and global suppliers, who may opt to redirect flows elsewhere or negotiate with alternative buyers, weakening the position of the U.S. as a key copper market.
Speculation about re-exports, mounting warehouse stocks, and mismatched price benchmarks could trigger further market inefficiency, raising the risk of forced liquidation sales or additional price shocks if inventory levels become unmanageable.
Even if fundamentals broadly stay unchanged, the policy-driven risk premium may linger, discouraging both physical investment and speculative participation—especially from overseas players wary of recurring, unpredictable U.S. interventions in key commodity markets.
The administration's patchwork approach—delaying refined copper levies until 2027 at 15%, rising to 30% in 2028—reflects a bid to secure domestic supply amid limited U.S. smelting capacity. Industry veterans caution that abrupt policy pivots could deter long-term investment in critical base-metal infrastructure. Despite the upheaval, analysts at Goldman Sachs argue that the tariff carve-outs leave copper's demand-and-supply dynamics largely intact, forecasting Comex prices to track LME levels over the coming months. For now, traders and producers alike will be bracing for a period of tactical repositioning as the dust settles on one of the commodity world's most spectacular policy-driven reversals.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SIS, LLC Announces Successful Go-Live of CRB on Microsoft Dynamics 365 and SIS Construct 365 Project Cost Management
SIS, LLC Announces Successful Go-Live of CRB on Microsoft Dynamics 365 and SIS Construct 365 Project Cost Management

Globe and Mail

time14 minutes ago

  • Globe and Mail

SIS, LLC Announces Successful Go-Live of CRB on Microsoft Dynamics 365 and SIS Construct 365 Project Cost Management

DULUTH, Ga., Aug. 6, 2025 /CNW/ -- SIS, LLC, a Microsoft Solutions Partner for Business Applications and leading implementer of ERP and CRM solutions for the construction industry, is thrilled to announce the successful go-live of CRB Group on Microsoft Dynamics 365 (D365) and SIS Construct 365 Project Cost Management (PCM) solution. This milestone marks a significant step in CRB's digital transformation journey, empowering their teams with cutting-edge tools to drive efficiency, profitability, and growth.

DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands

Globe and Mail

time40 minutes ago

  • Globe and Mail

DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands

DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.95 in the second quarter of 2025, up 13.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.3%. GAAP EPS for the quarter was $2.58, reflecting an uptick of 3.2% year over year. DaVita's Revenues in Detail Revenues of $3.38 billion in the second quarter increased 6.1% year over year. The figure topped the Zacks Consensus Estimate by 1.3%. Revenue per treatment in the second quarter of 2025 was $404.6 million, up 3.7% year over year and 1.1% sequentially. Per management, this was primarily driven by normal seasonal improvements, including patients meeting their co-insurance and deductibles. This was partially offset by decreased volume of phosphate binders. Shares of this company plunged nearly 10.1% till last trading. DVA's Segment Details DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues. The dialysis patient service revenues were $3.21 billion, up 4.8% year over year. Other revenues were $172.7 million, up 37.4% from the year-ago quarter's figure. Per management, the total U.S. dialysis treatments for the second quarter were 7,186,217 or 92,131 per day, on average. This represents a per-day increase of 0.4% on a sequential basis. Normalized non-acquired treatment declined 0.8% year over year in the second quarter of 2025. As of June 30, 2025, DaVita provided dialysis services to around 283,100 patients at 3,175 outpatient dialysis centers, of which 2,662 were U.S. centers while 513 were located across 13 other countries. During the second quarter of 2025, the company acquired one, opened three and closed two dialysis centers in the United States. It also opened six and closed five dialysis centers outside the United States in the same period. As of June 30, 2025, DaVita had approximately 64,400 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.3 billion in annualized medical spend. The company also had an additional 9,300 patients in other integrated care arrangements. DaVita's Margin Details In the quarter under review, DaVita's gross profit increased 7% year over year to $1.12 billion. The gross margin expanded 31 basis points (bps) to 33.1%. General & administrative expenses climbed 12.2% year over year to $412.8 million. Adjusted operating profit totaled $705.2 million, reflecting a 4.2% increase from the prior-year quarter's level. Adjusted operating margin in the second quarter contracted 36 bps to 20.9%. DVA's Financial Position DaVita exited second-quarter 2025 with cash and cash equivalents and short-term investments of $739.4 million compared with $511.9 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2025 was $10.26 billion compared with $9.74 billion at the first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter 2025 was $504.2 million compared with $664 million a year ago. During the three months ended June 30, 2025, DVA repurchased 3.1 million shares for $446 million. DaVita's Guidance DaVita has reiterated its adjusted EPS outlook for 2025. Adjusted EPS for the full year is continued to be projected in the range of $10.20-$11.30. The Zacks Consensus Estimate currently stands at $10.76. Our Take on DVA DaVita ended the second quarter of 2025 with better-than-expected results. The uptick in the company's top and bottom lines and revenue per treatment was encouraging. The per-day increase in total U.S. dialysis treatments for the second quarter on a sequential basis and solid revenues from both sources were encouraging. The opening and acquiring of dialysis centers within the United States and acquiring centers overseas were promising. The gross margin expansion bodes well for the stock. However, the year-over-year decline in normalized non-acquired treatment was disappointing. The contraction of the adjusted operating margin does not bode well for the stock. DaVita's Zacks Rank and Key Picks DVA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store